Aerovate Therapeutics Announces Full-Year 2023 Financial
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...
Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly...
By Colin Kellaher Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its anemia drug Reblozyl. The...
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Earnings and Valuation This table compares Fulcrum Therapeutics […]
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation. Profitability This table compares Fulcrum Therapeutics and Vertex […]